(Q37397788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

quality-adjusted life year

21 January 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Beatriz G Lopez-Valcarcel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

14 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

444-448

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232368%20AND%20SRC:MED&resulttype=core&format=json

Economic evaluations of human papillomavirus vaccines

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness of human papillomavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Do we fully understand the economic value of vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Evolution of the health economics of cervical cancer vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-utility analysis of vaccination against HPV in Israel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Chapter 19: Cost-effectiveness of cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Human Papillomavirus Vaccination — Reasons for Caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Health and economic implications of HPV vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Screening for cervical cancer in the era of the HPV vaccine--the urgent need for both new screening guidelines and new biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness analyses of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Trade-offs in cervical cancer prevention: balancing benefits and risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011

Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2009.02.011